Century Therapeutics (NASDAQ:IPSC) SVP Douglas Carr Sells 7,043 Shares

Century Therapeutics, Inc. (NASDAQ:IPSC) SVP Douglas Carr sold 7,043 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $2.55, for a total transaction of $17,959.65. Following the sale, the senior vice president owned 507,261 shares of the company’s stock, valued at $1,293,515.55. This represents a 1.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Douglas Carr also recently made the following trade(s):

• On Tuesday, February 3rd, Douglas Carr sold 323 shares of Century Therapeutics stock. The shares were sold at an average price of $1.82, for a total transaction of $587.86.

Century Therapeutics Stock Performance

NASDAQ IPSC traded up $0.09 during trading hours on Monday, hitting $2.43. The company had a trading volume of 815,753 shares, compared to its average volume of 1,847,081. Century Therapeutics, Inc. has a 1-year low of $0.34 and a 1-year high of $3.04. The company has a market cap of $212.39 million, a PE ratio of -17.36 and a beta of 1.70. The business has a 50 day moving average of $2.08 and a 200-day moving average of $1.12.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. Sell-side analysts expect that Century Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IPSC. TD Cowen began coverage on Century Therapeutics in a research note on Wednesday, February 25th. They issued a “buy” rating for the company. Piper Sandler raised their target price on shares of Century Therapeutics from $2.00 to $4.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Wall Street Zen raised shares of Century Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Zacks Research downgraded shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Finally, Leerink Partners set a $2.00 price target on shares of Century Therapeutics and gave the stock a “market perform” rating in a research note on Friday. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $3.80.

Institutional Trading of Century Therapeutics

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its stake in shares of Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after buying an additional 34,466 shares in the last quarter. AQR Capital Management LLC raised its position in Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after acquiring an additional 86,875 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Century Therapeutics by 26.9% in the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock worth $86,000 after acquiring an additional 38,052 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Century Therapeutics by 101.2% in the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after acquiring an additional 142,953 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in Century Therapeutics in the second quarter valued at $25,000. 50.20% of the stock is owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.